small-cell lung cancer
AbbVie shuts down Rova-T development in first-line advanced small-cell lung cancer following another trial failure
August 30, 2019Medical Communications, Research and Development AbbVie, pharma, rova-t, small-cell lung cancer
AbbVie has announced its intention to terminate development of Rova-T (rovalpituzumab tesirine) in the first-line maintenance of advanced small-cell lung …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
